REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad – 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated August 22, 2020

To,
National Stock Exchange of India Limited,
BSE Limited
Symbol: GRANULES Scrip Code: 532482

Sub: Granules Pharmaceuticals, Inc. received US FDA approval for Ramelteon Tablets, 8 mg
Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir,

Please be informed that, the US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc (GPI)., a wholly owned foreign subsidiary of Granules India Limited for Ramelteon Tablets, 8 mg. It is bioequivalent to the reference listed drug product (RLD), Rozerem Tablets, 8 mg, of Takeda Pharmaceuticals U.S.A., Inc. Ramelteon Tablets are used for the treatment of insomnia characterized by difficulty with sleep onset.

Granules now has a total of 29 ANDA approvals from US FDA (27 Final approvals and 2 tentative approvals).

Ramelteon Tablets had U.S. sales of approximately $33 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.

Rozerem® is a trademark of Takeda Pharmaceutical Company Limited.

This is for your information and dissemination to the members

Thanking you.

Yours faithfully

FOR GRANULES INDIA LIMITED

GRANULES INDIA LIMITED Hyderabad

CHAITANYA TUMMALA
COMPANY SECRETARY
COMPLIANCE OFFICER